What is Clinical Laserthermia Systems AB PB Ratio?
Clinical Laserthermia Systems ABFRA:LS60 -2.91%36 PB Ratio is 1.48 as of Jun. 24, 2026, which is 82% below its 10-year median of 8.10. GuruFocus rates FRA:LS60 with a GF Score™ of 36/100 and a GF Value™ of €0.29 (Fairly Valued). The stock has 4 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Clinical Laserthermia Systems AB ranks better than 56.42% on this metric.
FRA:LS60'
s PB Ratio Range Over the Past 10 Years
Min: 0.82 Med: 8.1 Max: 409.85
Current: 1.83
During the past 13 years, Clinical Laserthermia Systems AB's highest PB Ratio was 409.85. The lowest was 0.82. And the median was 8.10.
FRA:LS60's PB Ratio is ranked better than 56.42% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs FRA:LS60: 1.83
During the past 12 months, Clinical Laserthermia Systems AB's average Book Value Per Share Growth Rate was -32.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -32.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -27.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Clinical Laserthermia Systems AB was 27.00% per year. The lowest was -41.20% per year. And the median was -20.40% per year.
Back to Basics: PB Ratio
Clinical Laserthermia Systems AB (FRA:LS60) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Clinical Laserthermia Systems AB PB Ratio Related Terms
Clinical Laserthermia Systems AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Clinical Laserthermia Systems AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinical Laserthermia Systems AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Clinical Laserthermia Systems AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Clinical Laserthermia Systems AB's PB Ratio falls into.
Clinical Laserthermia Systems AB PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Clinical Laserthermia Systems AB (FRA:LS60) has a PB Ratio of 1.48 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Clinical Laserthermia Systems AB and its competitors. This is 82% below median its historical median of 8.10. Over the past decade, Clinical Laserthermia Systems AB's PB Ratio has ranged from 0.82 to 409.85. According to the industry distribution chart, Clinical Laserthermia Systems AB ranks #343 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 43.6%.
Is Clinical Laserthermia Systems AB's PB Ratio too high?
Clinical Laserthermia Systems AB's current PB Ratio of 1.48 is 82% below median its 10-year median of 8.10. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 409.85. The Medical Devices & Instruments industry median PB Ratio is 2.04. Clinical Laserthermia Systems AB's value of 1.48 is 27.5% below this industry median. Based on the distribution chart, Clinical Laserthermia Systems AB ranks #343 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Clinical Laserthermia Systems AB ranks #343 out of 787 companies for PB Ratio. This puts Clinical Laserthermia Systems AB in the upper half of its industry. The industry median PB Ratio is 2.04. Clinical Laserthermia Systems AB's value of 1.48 is 27.5% below this benchmark. Historically, Clinical Laserthermia Systems AB's own PB Ratio has ranged from 0.82 to 409.85 over the past decade. While the company's 10-year median is 8.10 vs. the industry median of 2.04, Clinical Laserthermia Systems AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinical Laserthermia Systems AB's current PB Ratio of 1.48 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Clinical Laserthermia Systems AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinical Laserthermia Systems AB's current PB Ratio is 1.48, which is 82% below median its own 10-year median of 8.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (FRA:LS60) is currently considered Fairly Valued. The stock's GF Value™ is €0.29, compared to a current price of €0.27 — trading 7.9% below its estimated fair value. The current PB Ratio is 1.48, which is 82% below median its 10-year median of 8.10 and 27.5% below the Medical Devices & Instruments industry median of 2.04. Clinical Laserthermia Systems AB's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (FRA:LS60), the current PB Ratio is 1.48 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinical Laserthermia Systems AB (FRA:LS60) Overvalued in 2026?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued.
The current stock price of €0.27 is trading 7.9% below its estimated GF Value™ of €0.29.
GuruFocus considers Clinical Laserthermia Systems AB to be Fairly Valued.
Key valuation signals for FRA:LS60:
PB Ratio: 1.48 (82% below median its 10-year median of 8.10)
GF Value™: €0.29 vs. price of €0.27 (7.9% below fair value)
Industry Position: 27.5% below the Medical Devices & Instruments median (#343 of 787)
No single metric tells the full story. See the FRA:LS60 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinical Laserthermia Systems AB Business Description
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
36GF Score
Get the complete analysis for FRA:LS60
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LS60 has been successfully added to your 
